A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

• Status: Completed
• Trial end date: 2013-04-01

Summary

A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.

• Phase: Phase 2

Details

• Lead Sponsor: Aerie Pharmaceuticals
• Treatments: Maleic acid; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol